Circulating nucleic acids as biomarkers of prostate cancer

Biomarkers in Medicine

Volumn 7, Issue 6, 2013, Pages 867-877

  Sita Lumsden, Ailsa ^a   Fletcher, Claire E ^a   Dart, D Alwyn ^a,b   Brooke, Greg N ^a,c   Waxman, Jonathan ^a   Bevan, Charlotte L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

biomarkers; cell free DNA; circulating nucleic acids; microRNA; miRNA; mRNA; prostate cancer

Indexed keywords

AGR2 PROTEIN; BONE MORPHOGENETIC PROTEIN 6; CELL FREE CIRCULATING DNA; CIRCULATING MIRNA; CIRCULATING MRNA; DOCETAXEL; HISTONE H3; LET 7C; LET 7E; LET 7I; MICRORNA 106A; MICRORNA 1285; MICRORNA 141; MICRORNA 195; MICRORNA 200B; MICRORNA 20A; MICRORNA 21; MICRORNA 221; MICRORNA 24; MICRORNA 26A; MICRORNA 27A; MICRORNA 30C; MICRORNA 375; MICRORNA 622; MICRORNA 93; MITOCHONDRIAL DNA; NUCLEIC ACID; PROSTATE SPECIFIC ANTIGEN; TELOMERASE; UNCLASSIFIED DRUG;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DNA CONTENT; DNA METHYLATION; EPIGENETICS; HUMAN; MICROSATELLITE INSTABILITY; MUTATION; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RARB2 GENE; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVIEW; RNF219 GENE; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

DNA; DNA METHYLATION; DNA, MITOCHONDRIAL; HUMANS; MALE; MICRORNAS; NUCLEIC ACIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84889574830     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.104     Document Type: Review

References (82)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Schroder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr. Opin. Urol. 19(3), 227-231 (2009).
3. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004).
4. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J. Urol. 162(2), 293-306 (1999). (Pubitemid 29434327)
5. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J. Urol. 190(2), 389-398 (2013).
6. Nam RK, Sugar L, Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 97(12), 1690-1695 (2007). (Pubitemid 350249347)
7. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. CR Acad. Sci. Paris 142, 241-243 (1948).
8. Leon S, Shapiro B, Sklaroff D, Yaros M. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37(3), 646-650 (1977). (Pubitemid 8051621)
9. Delgado P, Alves B, Sousa Gehrke F et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumor Biol. 34(2), 983-986 (2013).
10. Altimari A, Grigioni AD, Benedettini E et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Res. 129(5), 756-762 (2008).
11. Ellinger J, Müller SC, Wernert N, von Ruecker A, Bastian PJ. Mitochondrial DNA in serum of patients with prostate cancer: A predictor of biochemical recurrence after prostatectomy. BJU Int. 102(5), 628-632 (2008).
12. Bastian PJ, Palapattu GS, Yegnasubramanian S et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin. Cancer Res. 13(18), 5361-5367 (2007). (Pubitemid 47510361)
13. Jung K, Stephan C, Lewandowski M et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 205(2), 173-180 (2004). (Pubitemid 38230124)
14. Schwarzenbach H, Alix-Panabières C, Müller I et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15(3), 1032-1038 (2009).
15. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001). (Pubitemid 34292602)
16. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5), 318-322 (1989). (Pubitemid 19216753)
17. Ellinger J, Müller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol. Oncol. 29(2), 124-129 (2011).
18. Jeronimo C, Nomoto S, Caballero O et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20(37), 5195-5198 (2001). (Pubitemid 32844048)
19. Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin. Cancer Res. 13(2), 421-426 (2007). (Pubitemid 46225345)
20. Ellinger J, Müller DC, Müller SC et al. Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies. Urol. Oncol. 30(4), 509-515 (2012).
21. Müller I, Urban K, Pantel K, Schwarzenbach H Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann. NY Acad. Sci. 1075(1), 222-229 (2006). (Pubitemid 44532788)
22. Schwarzenbach H, Chun FKH, Lange I et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int. J. Cancer 120(7), 1465-1471 (2007). (Pubitemid 46355381)
23. Schwarzenbach H, Chun FK, Müller I et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 102(2), 253-258 (2008). (Pubitemid 351852597)
24. Sunami E, Shinozaki M, Higano CS et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem. 55(3), 559-567 (2009).
25. Papadopoulou E, Davilas E, Sotiriou V et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. NY Acad. Sci. 1075(1), 235-243 (2006). (Pubitemid 44532790)
26. Goessl C, Muller M, Miller K. Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis. 3, S17-S17 (2000).
27. Ellinger J, Haan K, Heukamp LC et al. CpG Island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1), 42-49 (2008).
28. Jernimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60(6), 1131-1135 (2002). (Pubitemid 35447593)
29. Reibenwein J, Pils D, Horak P et al. Promoter hypermethylation of GSTP1, AR and 14-13-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67(4), 427-432 (2007). (Pubitemid 46341084)
30. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP. Methylation-specific sequencing of GSTP1 gene promoter in circulating/ extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. NY Acad. Sci. 1137(1), 222-225 (2008).
31. Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev. 31(1), 59-63 (2007).
32. Bastian PJ, Palapattu GS, Yegnasubramanian S et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol. 179(2), 529-534 (2008).
33. Goessl C, Krause H, Müller M et al. fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60(21), 5941-5945 (2000).
34. Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6(6), 443-450 (1997). (Pubitemid 27270550)
35. Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-Transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91(24), 11733-11737 (1994). (Pubitemid 24356419)
36. Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7(6), 531-536 (1998). (Pubitemid 28354117)
37. Nakayama M, Bennett CJ, Hicks JL et al. Hypermethylation of the human glutathione S-Transferase-P gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am. J. Pathol. 163(3), 923-933 (2003). (Pubitemid 37040128)
38. Jerónimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93(22), 1747-1752 (2001). (Pubitemid 33130264)
39. Goessl C, Müller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann. NY Acad. Sci. 945(1), 51-58 (2001). (Pubitemid 33022431)
40. Bastian PJ, Palapattu GS, Lin X et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11(11), 4037-4043 (2005). (Pubitemid 40791567)
41. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J. Urol. 158(6), 2162-2167 (1997). (Pubitemid 27481350)
42. Chon CH, Lai FC, McNeal JE, Presti JC Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J. Urol. 167(6), 2457-2460 (2002). (Pubitemid 34533145)
43. Liu L, Yoon J, Dammann R, Pfeifer G. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21(44), 6835-6840 (2002). (Pubitemid 35221926)
44. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8(2), 514-519 (2002). (Pubitemid 34193971)
45. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 202(2), 233-240 (2004). (Pubitemid 38208661)
46. Nakayama T, Watanabe M, Yamanaka M et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab. Invest. 81(7), 1049-1057 (2001). (Pubitemid 32645980)
47. Cortese R, Kwan A, Lalonde E et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Hum. Mol. Genet. 21(16), 3619-3631 (2012).
48. He LR, Liu MZ, Li BK et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 9(1), 461 (2009).
49. Ke X-S, Qu Y, Rostad K et al. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE 4(3), e4687 (2009).
50. Deligezer U, Yaman F, Darendeliler E et al. Post-Treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin. Chim. Acta 411(19-20), 1452-1456 (2010).
51. Moreno JG, O'Hara SM, Long JP et al. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology 49(4), 515-520 (1997). (Pubitemid 27161408)
52. Polascik T, Wang Z, Shue M et al. Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. J. Urol. 162, 749-752 (1999). (Pubitemid 29436865)
53. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 65(18), 8274-8285 (2005). (Pubitemid 41330592)
54. Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod. Pathol. 21(12), 1436-1443 (2008).
55. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin. Cancer Res. 10(12), 3943-3953 (2004). (Pubitemid 38812467)
56. Dalle Carbonare L, Gasparetto A, Donatelli L, Dellantonio A, Valenti MT. Telomerase mRNA detection in serum of patients with prostate cancer. Urol. Oncol. 31(2), 205-210 (2013).
57. Dasí F, Martínez-Rodes P, March JA et al. Real-Time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann. NY Acad. Sci. 1075(1), 204-210 (2006). (Pubitemid 44532786)
58. March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Aliño SF, Dasí F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS ONE 7(8), e43470 (2012).
59. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 43(3), 249-259 (2005). (Pubitemid 40726870)
60. Bu H, Bormann S, Schäfer G et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71(6), 575-587 (2011).
61. Kani K, Malihi PD, Jiang Y et al. Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate 73(3), 306-315 (2013).
62. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin 4 encodes small RNAs with antisense complementarity to lin 14. Cell 75(5), 843-854 (1993). (Pubitemid 24014542)
63. Heneghan HM, Miller N, Kerin MJ. miRNAs as biomarkers and therapeutic targets in cancer. Curr. Opin. Pharmacol. 10(5), 543-550 (2010).
64. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez- Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - The mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8(8), 467-477 (2011).
65. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008). (Pubitemid 351853251)
66. Hastings ML, Palma J, Duelli DM. Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods 58(2), 144-150 (2012).
67. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149(3), 192-199 (2008).
68. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105(30), 10513-10518 (2008).
69. Moltzahn F, Olshen AB, Baehner L et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71(2), 550-560 (2011).
70. Bryant RJ, Pawlowski T, Catto JW et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106(4), 768-774 (2012).
71. Chen ZH, Zhang GL, Li HR et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72(13), 1443-1452 (2012).
72. Yaman Agaoglu F, Kovancilar M, Dizdar Y et al. Investigation of miR 21, miR 141, and miR 221 in blood circulation of patients with prostate cancer. Tumour Biol. 32(3), 583-588 (2011).
73. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265.e9-e16 (2011).
74. Waltering KK, Porkka KP, Jalava SE et al. Androgen regulation of micro-RNAs in prostate cancer. Prostate 71(6), 604-614 (2011).
75. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR 27a, which targets Prohibitin in prostate cancer. Hum. Mol. Genet. 21(14), 3112-3127 (2012).
76. Greene KL, Meng MV, Elkin EP et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from cancer of the prostate strategic urological research endeavor (capsure). J. Urol. 171(6 Pt 1), 2255-2259 (2004). (Pubitemid 38625446)
77. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J. Clin. Oncol. 23(32), 8146-8151 (2005). (Pubitemid 46211547)
78. Brase JC, Johannes M, Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128(3), 608-616 (2011).
79. Nguyen HC, Xie W, Yang M et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73(4), 346-354 (2013).
80. Shen J, Hruby GW, McKiernan JM et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72(13), 1469-1477 (2012).
81. Zhang HL, Yang LF, Zhu Y et al. Serum miRNA 21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71(3), 326-331 (2011).
82. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 9(1), 39-45 (2011).